BACKGROUND: Lipoprotein(a) is a risk factor for @entity453 . Although it has been implicated in @entity256 after balloon angioplasty, its role in @entity256 within coronary stents is unknown. The aim of the study was to assess the role of plasma lipoprotein(a) as a predictor for @entity256 after elective coronary stenting. METHODS AND RESULTS: Elective, high-pressure stenting of de novo lesions in native coronary arteries with Palmaz-Schatz stents was performed in 325 consecutive @entity1 . Clinical, angiographic, and biochemical data were analyzed prospectively. Angiographic follow-up was performed at 6 months. Lipoprotein(a) levels were compared in @entity1 with and without @entity256 . Angiographic follow-up was obtained in 312 @entity1 (96%); recurrence was observed in 67 @entity1 (21.5%). No clinical or biochemical variable was associated with @entity256 . Lipoprotein(a) level was 37.81+/-49. 01 mg/dL (median, 22 mg/dL; range, 3 to 262 mg/dL) in restenotic @entity1 and 36.95+/-40.65 mg/dL (median, 22 mg/dL; range, 0 to 244 mg/dL) in nonrestenotic @entity1 (P=NS). The correlations between percent diameter stenosis, minimum luminal diameter, and late loss at follow-up angiography and basal lipoprotein(a) plasma level after logarithmic transformation were 0.006, 0.002, and 0.0017, respectively. Multiple stents were associated with a higher incidence of @entity256 (P=0.006), but biochemical data in these @entity1 were similar to those treated with single stents. CONCLUSIONS: The basal plasma level of lipoprotein(a) measured before the procedure is not a predictor for @entity256 after elective high-pressure coronary stenting.

Plasma lipoprotein(a) is not a predictor for XXXX after elective high-pressure coronary stenting.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity453 :: ('MESH:D003324', 'Disease') :: ['coronary artery disease'] @entity256 :: ('MESH:D023903', 'Disease') :: ['restenosis']
@entity256 :: (MESH:D023903,Disease) :: ['restenosis']
